We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
You referring to the JV company set up by Avacta and Daewoong?
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that AffyXell Therapeutics (“AffyXell”), the joint venture with Daewoong Pharmaceutical (“Daewoong”), has closed a Series A venture capital investment of $7.3 million to further develop its pipeline of next generation cell and gene therapies.
I'm fairly sure it is another one.
Just listening again to try and catch it LDT.
Have been thinking a buy is being worked but obviously could be wrong.
After that interview they will need pliers to get any shares from me.
Onwards Avacta.
Richob: without listening could it have been AffyXell Therapeutics?
No I didn't richob.
Mrx seem very active on both sides of the book. Any thoughts?
Did anybody catch the name of the South Korean(?) company mentioned late on (not Daewoong). Keep listening but can't quite make it out. Thanks if anybody knows.
Onwards Avacta.
Excellent video. Magnificent CEO, Brilliant Company, and an interviewer rushing out to buy shares. No wonder the SP is on the rise , Paul will get a job as Head of Marketing. We complain about the lack of presentation and getting the message out there and here we have a man talking Symphonies and Mozart. One of the best analogies I've heard in a long time. The part where Al said TMAC was the area ALL the BIG Pharma's were interested in makes me wonder how this could pan out. I wonder if Mozart has a piano in that big new house of his, sitting there composing an aria for his next performance, .music to my ears.
Haha..I prefer dullness in the interviewer and zero knowledge. Bring back Giles.
Hayashi. What a cynic! For my own part I thought the interviewer was excellent. Knowledgeable, enthusiastic, clued up on all aspects of the business and asking all the relevant questions. That allowed Alistair to be more animated than we have seen for a while, and what a story he has to tell!!
Fair enough doze. But if the interviewer can pile in before might that not alter the tone/content of the questions. I mean he could hardly contain himself...'tell us all how wonderful and massive it will all be and how your sp will soar away' (dont tell anyone but I have loads of them)
Certainly a contrast in interviewing styles between Paul and Giles. Not sure who I prefer. If it were possible this video pinned to the top of the board would easily assist any potential investors with an up to date state of the nation.
hayashi, don't be cynical, he is a professional investor and has contributed to tip sheets in the past so hype and excitement is what he is about. Most on this board get the excitement of investing and if Paul Hill invested 8 months ago it is nothing to do with seeing an excited CEO a few days before an interview in lockdown conditions.
was the actual voice of the interviewer dubbed by frank skinner
It was a great interview though I thought the interviewer was ghastly. Each to us own.
Giles perhaps too bland but that has some merit v the over-excited puppy approach.
Does anyone know how Vox works? Are the interviewers allowed to invest in the companies they are talking about.?
More pointedly is the interviewer allowed to load up ahead in the knowledge that the interview is likely to be positive??
Did anyone else notice , how alistar smith , could not speak highly enough of our chief development officer, Neil bell , I wonder what he’s pushing for us at the moment
What a great video. Enthusiastic, realistic and informative to all watching. Wait to the CE Mark and watch this fly! AVCT the company to watch at the moment!